When It Comes to Disease Prevention, Bill Gates Shoots for Big Numbers
Forbes’s Matthew Herper on Bill Gates on vaccines and pharma: There’s sufficient ink for undeniably venerable ideas and acts, but an “unimpressed” Gates disparages Novartis’s Gleevac, a molecule that has completely revolutionized the treatment of CML.
“There’s always this divergence between what’s financially attractive
and what has dramatic profit and the number of life years that you
really save…Do the math on [Gleevac]
versus, says, preventing Parkinson’s or preventing Alzheimer’s. It’s in a
different universe.“
A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on Google + and Twitter.
